$WERN

Werner Enterprises, Inc. Stock 12‑Month Price Target Cut to $41.53, Implies 27% Upside

Werner Enterprises' average stock price target decreased from $41.93 to $41.53, with estimates ranging from $33 to $55. This implies a 27% upside from the Oct. 6 closing price. Analysts' consensus rating remains 'Hold' with 5 Buys, 9 Holds, and 2 Sells.

Original reporting
Published Oct 7, 2026, 7:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 7:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Werner Enterprises, Inc. Stock 12‑Month Price Target Cut to $41.53, Implies 27% Upside — source image
Decision brief

The 30-second read

$WERNNeutralLow
01

Why it matters

The target reduction is a small negative catalyst but leaves a sizable upside thesis, likely resulting in limited price movement.

02

Market read

The price‑target change provides a modest, short‑term trading signal for WERN investors.

03

What to watch

Potential upcoming contract wins or fuel‑price dynamics could offset the modest target reduction.

Relevance 5/10Novelty 5/10Timing: today

Background

Werner Enterprises is a publicly traded U.S. trucking and logistics company. The article reports a recent analyst consensus price‑target adjustment.

Company-level read

Ticker impact

$WERNNeutralMedium confidence
Context

Analysts lowered Werner Enterprises' average 12‑month price target to $41.53, down from $41.93, implying about 27% upside from the current price.

Expected impact

potential modest downside as the target is reduced, but still room for upside versus current price

Evidence & confidence

A small downward revision of the price target suggests analysts see limited upside, likely tempering short‑term buying interest.

Market effects

Minor impact on the trucking and logistics sector as the target change reflects broader industry expectations.

Limited to U.S. equity markets; no broader regional effect.

Low global relevance; only affects investors tracking Werner Enterprises.

Counterpoint

Some investors may view the target cut as an entry point given the still‑large upside implied.

Key entities

  • Werner Enterprises, Inc.

    U.S. trucking and logistics provider (ticker WERN).

Related articles

$WERNMed

Werner CEO Leathers: just the 3rd inning in driver attrition

Werner Enterprises (NASDAQ: WERN) reported 2026 Q2 results and CEO Derek Leathers said driver attrition is only in the “third inning” of a supply-driven upcycle. Adjusted operating margin rose to 4.6% from 2.5% a year ago. One-Way revenue per truck per week rose to $6,114 from $4,787. Werner increased 2026 guidance, including Dedicated revenue per truck per week to up 3% to 5% and revenue per truck per mile to 10% to 13%.

$WERNMed

Werner Enterprises Reports Second Quarter 2026 Results

WERNER ENTERPRISES INC (WERN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 wern-2026x630xex991.htm EX-99.1 Document Exhibit 99.1 Werner Enterprises Reports Second Quarter 2026 Results Second Quarter 2026 Highlights (all metrics compared to second quarter 2025 ) • Total revenues of $933.9 million, increased $180.8 million, or 24% • Operating in

$CVXLow

Chevron announces senior leadership changes

Chevron (CVX) announced senior leadership changes effective January 1, 2027. Mark Nelson will focus on strategy and business development, Eimear Bonner will lead Oil, Products & Gas, Jeff Gustavson will become CFO, and Brent Gros will head New Energies and AI strategy. CEO Mike Wirth praised the new leaders' expertise and commitment.

$RAREHighAI 9/10

Ultragenyx agrees to sell voucher for US$210M

Ultragenyx Pharmaceutical (NASDAQ: RARE) agreed to sell a rare pediatric disease priority review voucher for $210M, nearly half its cash reserves. The deal, subject to regulatory approval, follows the FDA's August approval of its Genglycos gene therapy. Shares rose 2.97% on the news. Ultragenyx plans to use proceeds to advance rare disease therapies and support profitability. The price is within the range of recent voucher transactions, such as Rocket Pharmaceuticals' $180M deal.